OXB Share Price Performance
UK£0
-6.30 (-100.00%)
Price UK£0
Fair ValueUK£7.12
Share Pricen/a
Narrative Update • Aug 24
Oxford Biomedica plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 43 Fair Values set on narratives written by author
OXB Community Narratives
AN
Fair Value
·Fair Value UK£7.12 30.8% undervalued intrinsic discount
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
AN
Fair Value
·Fair Value UK£9.5 48.1% undervalued intrinsic discount
Expanding Global Cell And Gene Therapies Will Drive Vector Opportunities
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value UK£5.5 10.4% undervalued intrinsic discount
Rising Capital Costs And Fierce Competition Will Constrain CDMO Growth
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Oxford Biomedica
30.8% undervalued intrinsic discount
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
View narrativeAN
Updated 24 Aug
Oxford Biomedica
48.1% undervalued intrinsic discount
Expanding Global Cell And Gene Therapies Will Drive Vector Opportunities
View narrativeAN
Updated 10 Aug
Oxford Biomedica
10.4% undervalued intrinsic discount
Rising Capital Costs And Fierce Competition Will Constrain CDMO Growth
View narrativeAN
Updated 3 May
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
OXB: Future Upside Will Depend On Faster Revenue Conversion Execution
Fair Value: UK£7.12 30.8% undervalued intrinsic discount
27 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OXB: Viral Vector Execution And Durham Ramp Will Support Future Upside Potential
Fair Value: UK£9.5 48.1% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OXB: Future Cash Generation And Execution Risks Will Shape Balanced Outlook
Fair Value: UK£5.5 10.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Oxford Biomedica plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 24, 2026
- -0.25
- 39.10%
- -17.85%
- 45.4%
About OXB
- Founded
- 1996
- Employees
- 977
- CEO
- WebsiteView website
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play’ dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
